AUSTIN, Texas , Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced that it has filed a lawsuit in federal court against certain individuals who executed a “short and distort” campaign against the Company.
Chris Cook , A Skilled Litigator, To Join Management Team as General Counsel New Position Is Expected to Be Critical to Operations and Strategic Initiatives AUSTIN, Texas , Oct. 27, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on
Alzheimer’s Patients Who Complete Participation in a Phase 3 Study of Simufilam are Eligible to Enroll 52-week Study of Simufilam 100 mg Up to 1,600 Patients Are Expected to Enroll AUSTIN, Texas , Oct. 13, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc.
AUSTIN, Texas , Sept. 08, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it has been invited to present a corporate overview at the H.C. Wainwright 24 th Annual Global Investment Conference
AUSTIN, Texas , Aug. 18, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, was recently informed by the Journal of Prevention of Alzheimer's Disease (JPAD) that there is no convincing evidence to support
Phase 3 Program - Over 400 Patients Are Now Enrolled in Our Phase 3 Clinical Studies. Open-label Study – Results of an Interim Analysis on the First 100 Patients Who Have Completed at Least 12 Months of Open-label Treatment with Simufilam Follow: Drug Appears Safe and Well Tolerated.
- In November 2021 , Cassava Sciences previously disclosed that certain government agencies had asked for corporate information and at that time, the media widely reported on these prior disclosures. - No government agency has informed Cassava Sciences that it has found any evidence of research
- $209.7 Million Cash and Cash Equivalents at March 31, 2022 – - Over 120 Patients Now Enrolled in Phase 3 Program - AUSTIN, Texas , May 05, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced
- Q&A Session at Conference on Wednesday, April 27 th at 1:30PM Eastern - AUSTIN, Texas , April 25, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to participate in the
– All Stakeholder Are Welcome to Listen by Webcast – – Event To Be Held Tuesday, April 5 th , 9am ET – AUSTIN, Texas , April 04, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced webcast details for
